Pharmacyclics down 6%, still no Imbruvica CLL update
This article was originally published in Scrip
Executive Summary
Pharmacyclics saw its stock sink on the 9 December after extended Phase II trial data for oral Bruton's tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) was released at the 55th American Society for Hematology meeting in New Orleans. Although, the data continue to paint a positive picture, investors seem to be getting impatient for an update on the firms US CLL approval filing.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.